Buckwheat resistant starch alleviates hyperlipidaemia in mice by inhibiting lipid accumulation and regulating gut...

Hyperlipidemia, a prevalent metabolic disorder disease, has become a significant global health challenge. In this research, we looked into the effects of buckwheat resistant starch (BRS) supplementation on lipid metabolism and gut microbiota in hyperlipidemic mice. Results showed that HBRS intervention significantly inhibited weight gain in high-fat diet mice, reducing body weight by 2.91 g versus MC group. Serum TC, TG, and LDL-C decreased by 74.25 %, 76.79 %, and 56.25 % respectively, while HDL-C increased by 67.66 %. HBRS mitigated hepatic steatosis and epididymal adipocyte hypertrophy. HBRS downregulated TNF-α and IL-6 by 24.4 % and 18.25 %, respectively, and upregulated IL-10 by 15.35 %. It modulated lipid metabolism genes by suppressing SREBP2, FAS, SCD1 and activating PPARα/CPT1. Moreover, BRS improved gut microbiota composition by lowering the F/B ratio and enhancing populations of SCFA-producing bacteria (e.g., Akkermansia, Bifidobacterium, and Parabacteroides). BRS significantly increased the total levels of SCFAs in the gut. Compared to the MC group, HBRS resulted in increases of 40.2 %, 51.8 %, and 68.3 % in acetate, propionate, and butyrate, respectively. Collectively, these results demonstrate that BRS serves as a beneficial nutritional resource for the management of hyperlipidemia.